Get started
Alto Neuroscience, Inc.Alto Neuroscience, Inc.Alto Neuroscience, Inc.

Alto Neuroscience, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityForecastsSeasonalsETFs
Full chart
Full chart

Compare with Alto Neuroscience, Inc.



Key stats


Market capitalization
‪1.04 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.48 USD
Net income (FY)
‪−63.24 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪35.14 M‬
Beta (1Y)
2.36

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
68
Change (1Y)
−8−10.53%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

Details


Sector
Health Technology
Industry
Biotechnology
CEO
Amit Etkin
Website
altoneuroscience.com
Headquarters
Mountain View
Founded
2019
IPO date
Feb 2, 2024
ISIN
US02157Q1094
CUSIP
02157Q109
FIGI
BBG01V7ZD3C1
Identifiers
ISIN US02157Q1094
CFI code
ESVUFR
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


IWO
iShares Russell 2000 Growth Fund
Weight0.04%
Market value‪6.36 M‬
IBB
iShares Biotechnology ETF
Weight0.07%
Market value‪6.25 M‬
XPH
State Street SPDR S&P Pharmaceuticals ETF
Weight1.18%
Market value‪5.63 M‬
IWC
iShares Microcap ETF
Weight0.17%
Market value‪2.39 M‬
PSIL
AdvisorShares Psychedelics ETF
Weight4.47%
Market value‪2.19 M‬
VFMO
Vanguard U.S. Momentum Factor ETF
Weight0.08%
Market value‪1.54 M‬
SBIO
ALPS Medical Breakthroughs ETF
Weight0.51%
Market value‪1.03 M‬
VTWG
Vanguard Russell 2000 Growth ETF
Weight0.04%
Market value‪740.42 K‬
AVSC
Avantis U.S Small Cap Equity ETF
Weight0.02%
Market value‪575.80 K‬
GSSC
GS ActiveBeta U.S. Small Cap Equity ETF
Weight0.05%
Market value‪493.18 K‬
BBC
Virtus Biotech Clinical Trials ETF
Weight0.82%
Market value‪387.67 K‬

Explore more ETFs 

Frequently asked questions


Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange Alto Neuroscience, Inc. stocks are traded under the ticker ANRO.
We've gathered analysts' opinions on Alto Neuroscience, Inc. future price: according to them, ANRO price has a max estimate of 50.00 USD and a min estimate of 24.00 USD. Watch ANRO chart and read a more detailed Alto Neuroscience, Inc. stock forecast: see what analysts think of Alto Neuroscience, Inc. and suggest that you do with its stocks.
ANRO reached its all-time high on Apr 20, 2026 with the price of 28.10 USD, and its all-time low was 2.00 USD and was reached on Apr 2, 2025. View more price dynamics on ANRO chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Alto Neuroscience, Inc. financials in yearly and quarterly reports right on TradingView.
Alto Neuroscience, Inc. is going to release the next earnings report on Aug 19, 2026. Keep track of upcoming events with our Earnings Calendar.
ANRO earnings for the last quarter are −0.80 USD per share, whereas the estimation was −0.54 USD resulting in a −49.15% surprise. The estimated earnings for the next quarter are −0.71 USD per share. See more details about Alto Neuroscience, Inc. earnings.
Alto Neuroscience, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ANRO net income for the last quarter is ‪−26.24 M‬ USD, while the quarter before that showed ‪−16.18 M‬ USD of net income which accounts for 0.00% change. Track more Alto Neuroscience, Inc. financial stats to get the full picture.
No, ANRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 25, 2026, the company has 68 employees. See our rating of the largest employees — is Alto Neuroscience, Inc. on this list?
Like other stocks, ANRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alto Neuroscience, Inc. stock right from TradingView charts — choose your broker and connect to your account.